Figure 2.
RADIANT: Phase III trial of adjuvant erlotinib after surgical resection of stage IB–IIIA EGFR+ NSCLC.
Abbreviations: DFS, disease-free survival; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; OS, overall survival; RADIANT, Randomized Double-Blind Trial in Adjuvant NSCLC with Tarceva®.
